Levodopa–Entacapone–Carbidopa Intrajejunal Infusion in Advanced Parkinson's Disease – Interim Analysis of the ELEGANCE Study
Movement Disorders Clinical Practice · 2025-08 · 12 (8) · 1075-1085
DOI: 10.1002/mdc3.70046 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Movement Disorders Clinical Practice, online erschienen am 25.03.2025. Verfasst von Daniel Weiss und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department for Neurodegenerative Diseases, Centre for Neurology, Hertie-Institute for Clinical Brain Research, Tübingen, Germany. Hauptthemen laut MEDLINE: Parkinson Disease, Carbidopa, Levodopa, Antiparkinson Agents. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Britannia Pharmaceuticals.
Abstract (Originalsprache)
Background
Levodopa–entacapone–carbidopa intestinal gel (LECIG) was introduced in 2018 as a device‐aided therapy for advanced Parkinson's disease (PD).
Objectives
The ELEGANCE study (NCT05043103) is gathering real‐world data on long‐term efficacy, safety and patient‐reported outcomes with LECIG from 13 European countries. This article reports data from the planned interim analysis.
Methods
The study enrolled patients prescribed LECIG as part of routine clinical care. We evaluated patients at V1 before starting LECIG treatment (in seven patients V1 data were obtained retrospectively), and thereafter at V2 (3–6 months) or V3 (6–12 months).
Results
This analysis includes 167 patients from 37 centers. Three patients from this analysis set (1.8%) discontinued the study. Mean (±SD) daily OFF‐time hours (MDS‐UPDRS IV item 4.3) were substantially reduced by 3.47 ± 3.56 h at V2 (baseline: 5.15 ± 3.05; P < 0.0001). Similarly, MDS‐UPDRS part IV total scores were reduced by 4.24 ± 4.08 at V2 (baseline: 10.77 ± 3.83); ( P = 0.0001) and MDS‐UPDRS part II scores by 3.63 ± 7.76 at V2 (baseline: 20.65 ± 8.17; P = 0.0004). PDSS‐2 total scores were sustainably improved (reduction of 7.38 ± 10.72 at V2 [baseline: 25.21 ± 10.62]; P < 0.0001), as was the PDQ‐8 summary index score indicating an improvement in quality of life (QoL) (reduction of 13.3 ± 19.05 at V2 [baseline: 46.34 ± 20.09]; P < 0.0001). For all parameters improvements were maintained at V3. Patient‐reported satisfaction with the LECIG pump was high. Most adverse events were related to the procedure or the device.
Conclusions
Routine use of LECIG for up to 12 months provided sustained control of motor symptoms, and was well tolerated with a positive impact on QoL and high patient satisfaction.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department for Neurodegenerative Diseases, Centre for Neurology, Hertie-Institute for Clinical Brain Research, Tübingen, Germany.
- Parkinson-Klinik Ortenau, Wolfach, Germany.
- Department of Neurology, "George Emil Palade" University of Medicine, Pharmacy, Science and Technology, Târgu Mureș, Romania.
- Department of Neurology, University Medical Centre and Faculty of Medicine, Ljubljana, Slovenia.
- University Neurological Hospital "St. Naum", Sofia, Bulgaria.
- Gailtal-Klinik Hermagor, Neurorehabilitation, Austria.
ORCID-Profile: Daniel Weiss, Wolfgang H Jost, Teus van Laar
Förderung
- Britannia Pharmaceuticals
Zitieren
APA
Weiss, D., Jost, W. H., Szász, J. A., Pirtošek, Z., Milanov, I., Tomantschger, V., Kovács, N., Staines, H., Amlani, B., Smith, N., & van Laar, T. (2025). Levodopa–Entacapone–Carbidopa Intrajejunal Infusion in Advanced Parkinson's Disease – Interim Analysis of the ELEGANCE Study. Movement Disorders Clinical Practice, 12(8), 1075-1085. https://doi.org/10.1002/mdc3.70046
Vancouver
Weiss D, Jost WH, Szász JA, Pirtošek Z, Milanov I, Tomantschger V, et al. Levodopa–Entacapone–Carbidopa Intrajejunal Infusion in Advanced Parkinson's Disease – Interim Analysis of the ELEGANCE Study. Movement Disorders Clinical Practice. 2025;12(8):1075-1085. doi:10.1002/mdc3.70046
BibTeX
@article{Weiss2025,
author = {Weiss, Daniel and Jost, Wolfgang H and Szász, József Attila and Pirtošek, Zvezdan and Milanov, Ivan and Tomantschger, Volker and Kovács, Norbert and Staines, Harry and Amlani, Bharat and Smith, Niall and van Laar, Teus},
title = {Levodopa–Entacapone–Carbidopa Intrajejunal Infusion in Advanced Parkinson's Disease – Interim Analysis of the ELEGANCE Study},
journal = {Movement Disorders Clinical Practice},
year = {2025},
volume = {12},
number = {8},
pages = {1075--1085},
doi = {10.1002/mdc3.70046}
}
EUVIMED